The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Given these promising results and a strong scientific rationale, combined with LX-101’s novel mechanism of action and prior positive clinical experience in oncology, Lirum is planning new clinical ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, ...

Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit www.lirumtx.com. This press release contains ...